Skip to main content

Edan Dx Acquires LGC Molecular Diagnostic Platform

NEW YORK – Edan Diagnostics announced on Sunday it has acquired LGC’s Clarilight molecular diagnostics, point-of-care platform for an undisclosed amount.

The two firms have also agreed to partner to develop molecular diagnostic assays designed for Clarilight and for the supply of enzymes and oligonucleotides required for manufacturing. Edan will develop, manufacture, and market the instrument and test cartridges, as well as sell them.

Edan said it anticipates launching its initial products in two to three years.

Edan CEO Zhang Hao said in a statement that the acquisition will "jumpstart" the company’s entry into the the MDx market. Edan is a wholly owned subsidiary of Shenzhen, China-based Edan Instruments and is based in San Diego.

UK-based LGC is a life sciences firm offering products including genomics reagents and instruments, reference materials, and proficiency testing schemes.